Back to results
US 2022/0088178 A1Published application
Hiv vaccination compositions
AssigneeArizona Board of Regents on behalf of Arizona State University
InventorsTsafrir S. Leket-Mor, Bertram Jacobs, Lydia Meador, Karen Kibler
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions for generating an immune response against human immunodeficiency virus (HIV) and their methods of uses.
Claims20
A method of generating an immune response in a mammalian subject against HIV comprising:
- administering a vaccinia virus-like particle (VLP) to the mammalian subject, wherein the vaccinia VLP presents HIV Gag, a fragment of gp41, or both;
- and
- administering a plant-produced HIV VLP to the mammalian subject, wherein the plant-produced HIV VLP presents HIV Gag and a fragment of gp41 and is isolated from plant tissue transformed with a geminivirus-based plant expression vector,
- wherein the mammalian subject is administered the vaccinia VLP and the plant-produced HIV VLP in an amount sufficient to generate an HIV immune response in the mammalian subject.
1 more element
A method of generating an HIV immune response in a mammalian subject, the method comprising:
- administering a vaccinia virus-like particle (VLP) to the mammalian subject, wherein the vaccinia VLP presents HIV Gag and a fragment of gp41;
- and
- administering a plant-produced HIV VLP to the mammalian subject, wherein the plant-produced HIV VLP presents HIV Gag and a fragment of gp41 and is isolated from plant tissue transformed with a geminivirus-based plant expression vector,
- wherein the vaccinia VLP is isolated from a mammalian cell transfected with at least one replicating but highly attenuated vaccinia virus vector and the mammalian subject is administered the vaccinia VLP and the plant-produced HIV VLP in an amount sufficient to generate an HIV immune response in the mammalian subject.
1 more element
Dependencies are inferred from the claim text.